Evidence map›Paper›PMID 33022275›Full record

ArticleMolecular cell2020

Ubiquitin Phosphorylation at Thr12 Modulates the DNA Damage Response.

Franziska Walser, Monique P C Mulder, Benoît Bragantini, Sibylle Burger, Tatiana Gubser, Marco Gatti, Maria Victoria Botuyan, Alessandra Villa, Matthias Altmeyer, Dario Neri and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Decoding Ubiquitin Modifications by Mass Spectrometry.Advances in experimental medicine and biology · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Franziska WalserInstitute of Molecular Cancer Research, University of Zurich, 8057 Zurich, Switzerland.
Monique P C MulderDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, the Netherlands; Oncode Institute and Department of Cell and Chemical Biology, Chemical Immunology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.
Benoît BragantiniDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
Sibylle BurgerInstitute of Molecular Cancer Research, University of Zurich, 8057 Zurich, Switzerland.
Tatiana GubserInstitute of Molecular Cancer Research, University of Zurich, 8057 Zurich, Switzerland.
Marco GattiDepartment of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, Switzerland.
Maria Victoria BotuyanDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
Alessandra VillaDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich), 8093 Zurich, Switzerland.
Matthias AltmeyerDepartment of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, Switzerland.
Dario NeriDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich), 8093 Zurich, Switzerland.
Huib OvaaDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, the Netherlands; Oncode Institute and Department of Cell and Chemical Biology, Chemical Immunology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.
Georges MerDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
Lorenza PenengoInstitute of Molecular Cancer Research, University of Zurich, 8057 Zurich, Switzerland. Electronic address: penengo@imcr.uzh.ch.
University of Zurich · CHMayo Clinic · USETH Zurich · CHLeiden University Medical Center · NL

Funding

Structural Biology of Lysine Methylation in DNA Damage and Checkpoint SignalingR01CA132878 · NCI · MAYO CLINIC ROCHESTER · PI Georges Mer · 2008 to 2026
$4.5M
Structural biology of DNA damage response in chromatinR35GM136262 · NIGMS · MAYO CLINIC ROCHESTER · PI MER, GEORGES · 2020 to 2025
$4.2M
Structural basis of RNF168-mediated ubiquitin signaling at chromosomal DNA breaksR01GM116829 · NIGMS · MAYO CLINIC ROCHESTER · PI MER, GEORGES · 2015 to 2018
$1.3M
NCI NIH HHS R01 CA132878NIGMS NIH HHS R01 GM116829NIGMS NIH HHS R35 GM136262
6 · The paper itself

Abstract

The ubiquitin system regulates the DNA damage response (DDR) by modifying histone H2A at Lys15 (H2AK15ub) and triggering downstream signaling events. Here, we find that phosphorylation of ubiquitin at Thr12 (pUbT12) controls the DDR by inhibiting the function of 53BP1, a key factor for DNA double-strand break repair by non-homologous end joining (NHEJ). Detectable as a chromatin modification on H2AK15ub, pUbT12 accumulates in nuclear foci and is increased upon DNA damage. Mutating Thr12 prevents the removal of ubiquitin from H2AK15ub by USP51 deubiquitinating enzyme, leading to a pronounced accumulation of ubiquitinated chromatin. Chromatin modified by pUbT12 is inaccessible to 53BP1 but permissive to the homologous recombination (HR) proteins RNF169, RAD51, and the BRCA1/BARD1 complex. Phosphorylation of ubiquitin at Thr12 in the chromatin context is a new histone mark, H2AK15pUbT12, that regulates the DDR by hampering the activity of 53BP1 at damaged chromosomes.

Indexed as

AnimalsCell LineCell Line, TumorChromatinDNADNA-Binding ProteinsDNA Breaks, Double-StrandedDNA DamageDNA End-Joining RepairDNA RepairHistonesHomologous RecombinationHumansIntracellular Signaling Peptides and ProteinsNuclear ProteinsPhosphorylationChromatinDNADNA-Binding ProteinsHistonesIntracellular Signaling Peptides and ProteinsNuclear ProteinsThreonineTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1UbiquitinUbiquitin-Protein Ligases53BP1BRCA1/BARD1chromatin ubiquitinationDDRDNA damage responseDNA repairgenome stabilityH2AK15pUbT12histone mark H2AK15ubphospho-ubiquitin Thr12pUbT12RAD51RNF168RNF169RNF8ubiquitin phosphorylationUSP51

Identifiers

PMID33022275
PMCPMC7655664
OpenAlexW3090290656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.